Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Cullinan Therapeutics (CGEM) Tax Provisions (2022 - 2023)

Cullinan Therapeutics has reported Tax Provisions over the past 2 years, most recently at -$14.1 million for Q4 2023.

  • Quarterly results put Tax Provisions at -$14.1 million for Q4 2023, down 660.06% from a year ago — trailing twelve months through Dec 2023 was -$14.1 million (down 133.53% YoY), and the annual figure for FY2024 was $117000.0, up 100.83%.
  • Tax Provisions for Q4 2023 was -$14.1 million at Cullinan Therapeutics, down from -$1.9 million in the prior quarter.
  • Over the last five years, Tax Provisions for CGEM hit a ceiling of $66.1 million in Q2 2022 and a floor of -$19.6 million in Q1 2022.